drugset / Trial / NCT00473512
A Safety and Efficacy Study of Abiraterone Acetate in Participants With Prostate Cancer Who Have Failed Hormone Therapy
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the maximum tolerated dose and evaluate the safety, tolerability, and activity at the recommended dose (maximum tolerated dose \[MTD\]) of abiraterone acetate (also known as CB7630) in participants with hormone refractory prostate (gland that makes fluid that aids movement of sperm) cancer (HRPC).
Timeline
- Start
- 2005-11
- Primary completion
- 2008-11
- Completion
- 2008-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abiraterone acetate | Small molecule | 250 mg | Oral |
| Subject | Abiraterone acetate | Small molecule | 2000 mg | Oral |
| Background | Dexamethasone | Small molecule | 0.5 mg | Oral |